deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT01229111

Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers

A Phase 2 Study of AZD2171 (Cediranib) With Modified FOLFOX6 in Patients With Advanced Biliary Cancers

Sponsor: National Cancer Institute (NCI)

Conditions Adult Primary Cholangiocellular Carcinoma Advanced Adult Primary Liver Cancer Cholangiocarcinoma of the Extrahepatic Bile Duct Cholangiocarcinoma of the Gallbladder Localized Unresectable Adult Primary Liver Cancer Periampullary Adenocarcinoma Recurrent Adult Primary Liver Cancer Recurrent Extrahepatic Bile Duct Cancer Recurrent Gallbladder Cancer Unresectable Extrahepatic Bile Duct Cancer Unresectable Gallbladder Cancer
Interventions cediranib maleate fluorouracil leucovorin calcium oxaliplatin
Updated 8 times since 2017 Last updated: Feb 10, 2017 Started: Oct 31, 2010 Primary completion: Mar 31, 2014 Completion: Mar 31, 2014
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Lack of Drug Supply

Other terminated trials from National Cancer Institute (NCI)

See all terminations from National Cancer Institute (NCI)

Other Adult Primary Cholangiocellular Carcinoma trials with similar outcome

Browse all Adult Primary Cholangiocellular Carcinoma trials

Listed as NCT01229111, this PHASE2 trial focuses on Adult Primary Cholangiocellular Carcinoma and Advanced Adult Primary Liver Cancer and remains terminated or withdrawn. Sponsored by National Cancer Institute (NCI), it has been updated 8 times since 2010, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~May 2017 · 3 months · monthly snapshotCompleted~May 2017 – ~Jun 2018 · 13 months · monthly snapshotTerminated~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotTerminated~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotTerminated~Sep 2025 – present · 10 months · monthly snapshotTerminated

Change History

8 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE2

▶ Show 3 earlier versions

  1. May 2017 — Jun 2018 [monthly]

    Terminated PHASE2

    Status: Completed → Terminated

  2. Feb 2017 — May 2017 [monthly]

    Completed PHASE2

  3. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Oct 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations